The price of a drug should be based on its therapeutic benefits – not just what the market will bear

'Orphan drugs' with high price points are being tested as treatments for COVID-19. There's a better way to spur low-cost innovation for new drugs.

Nicole Hassoun, Professor of Philosophy, Binghamton University, State University of New York • conversation
Jan. 13, 2021 • ~9 min
covid-19 rheumatoid-arthritis remdesivir pharmaceutical-industry drug-development innovation-and-invention process-of-innovation gilead

Coronavirus: how the pharma industry is changing to produce a vaccine on time

Medical innovation is often accelerated in a time of crisis.

Stephen Morris, Research Fellow in Vaccine Process Analytics, UCL • conversation
Sept. 30, 2020 • ~8 min
biotechnology covid-19 vaccines pharmaceuticals coronavirus-2020 pharmaceutical-industry coronavirus-vaccine

Coronavirus vaccine search: how we're preparing to make enough for the whole world

The UK is investing heavily in preparation for mass manufacturing of a working COVID-19 vaccine.

Martina Micheletti, Professor of Bioprocess Fluid Dynamics, co-Director of the Future Vaccine Manufacturing Hub,, UCL • conversation
May 13, 2020 • ~8 min
covid-19 coronavirus manufacturing vaccines vaccination pharmaceutical-industry coronavirus-vaccine covid-19-vaccine

Coronavirus vaccine: how we're preparing to make enough for the whole world

The UK is investing heavily in preparation for mass manufacturing of a working COVID-19 vaccine.

Martina Micheletti, Professor of Bioprocess Fluid Dynamics, co-Director of the Future Vaccine Manufacturing Hub,, UCL • conversation
May 13, 2020 • ~8 min
covid-19 coronavirus manufacturing vaccines vaccination pharmaceutical-industry coronavirus-vaccine covid-19-vaccine

Medical supply chains are fragile in the best of times and COVID-19 will test their strength

Drug shortages occur regularly in the US, even in the best of times. The pharmaceutical supply chain embodies 'just in time' shipping and has little built-in redundancy.

Mark Daskin, Professor of Industrial and Operations Engineering, University of Michigan • conversation
March 25, 2020 • ~7 min

 drugs  pharmaceuticals  supply-chains  regulation  regulations  medicines  generic-medicines  generic-drugs  pharmaceutical-industry  medical-supply-chains

/

1